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Intrarenal interleukin-15 (IL-15) participates to renal pathophysiology, but the role of its different membrane-bound
isoforms remains to be elucidated. In this study, we reassess the biology of membrane-bound IL-15 (mb-IL-15)
isoforms by comparing primary cultures of human renal proximal tubular epithelial cells (RPTEC) to peritumoral
(ptumTEC), tumoral (RCC), and cancer stem cells (CSC/CD105+). RPTEC express a 14 to 16 kDa mb-IL-15, whose
existence has been assumed but never formally demonstrated and likely represents the isoform anchored at the cell
membrane through the IL-15 receptorα (IL-15Rα) chain, because it is sensitive to acidic treatment and is not competent
to deliver a reverse signal. By contrast, ptumTEC, RCC, and CSC express a novel N-hyperglycosylated, short-lived
transmembrane mb-IL-15 (tmb-IL-15) isoform around 27 kDa, resistant to acidic shock, delivering a reverse signal in
response to its soluble receptor (sIL-15Rα). This reverse signal triggers the down-regulation of the tumor suppressor
gene E-cadherin in ptumTEC and RCC but not in CSC/CD105+, where it promotes survival. Indeed, through the AKT
pathway, tmb-IL-15 protects CSC/CD105+ fromnon-programmedcell death induced by serumstarvation. Finally, both
mb-IL-15 and tmb-IL-15 are sensitive tometalloproteases, and the cleaved tmb-IL-15 (25 kDa) displays a powerful anti-
apoptotic effect on human hematopoietic cells. Overall, our data indicate that both mb-IL-15 and tmb-IL-15 isoforms
play a complex role in renal pathophysiology downregulating E-cadherin and favoring cell survival. Moreover,
“apparently normal” ptumTEC cells, sharing different properties with RCC, could contribute to organize an enlarged
peritumoral “preneoplastic” environment committed to favor tumor progression.
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Interleukin-15 (IL-15) is a pleiotropic cytokine that links in vivo innate
and adaptative immune responses and is characterized by the complexity
of its biology [1]. Indeed, IL-15 receptor (IL-15R) consists of a private
α-chain and shared IL-2 receptor β- and γ-chains that form various
functional receptors with different affinities and signaling capabilities
[2–7]. Moreover, several functional forms of IL-15 exist: 1) the soluble
monomeric form that is secreted at very low concentrations by accessory
cells and activates cells expressing the high affinity receptor [8], 2) the
soluble complex IL-15/IL-15Rα (sIL-15/IL-15Rα) that displays greater
half-life and bioavailability in comparison with monomeric IL-15 (N20
hours vs b40 minutes, respectively) and essentially interacts with cells
expressing low affinity IL-15R [4–7], 3) the membrane-bound form
(mb-IL-15), anchored at the cell membrane through the IL-15Rα chain
[5,9], and 4) the transmembrane form (tmb-IL-15) that is anchored
through an IL-15R–independent mechanism [1,10–12]. The sIL-15/
IL-15Rα [4–7] and the mb-IL-15 [8,13,14] represent the dominant
physiological forms of the cytokine. Although the mb-IL-15 and
tmb-IL-15 forms could deliver signal in trans to surrounding cells
expressing low affinity IL-15R [1,5,10–12], only the tmb-IL-15 delivers
a reverse signaling to presenting cells on stimulation with a recombinant
soluble IL-15Rα chain (sIL-15Rα) or anti–IL-15 antibodies [1,10–12].
Concerning non-lymphoid cells, human epithelial cells from different
tissues produce IL-15, involved not only in potential interactions with
immune cells but also in the biologic characteristics of epithelial cells
[15–23]. For instance, experiments in IL-15(−/−) and IL-15Rα(−/−)
mice show that intrarenal IL-15, through autocrine-paracrine and/or
juxtacrine loops, behaves as an epithelial survival factor through the
IL-15Rα chain [24,25]. In addition, recent data highlight new functions
of IL-15. Indeed, the cytokine elicits, through the IL-15Rγ/JAK3
pathway, a signaling cascade that preserves epithelial phenotype and
functions in normal human renal proximal tubular epithelial cells
(RPTEC) [26]. Moreover, IL-15 triggers epithelial differentiation of
renal cancer stem cells (CSC/CD105+) [27]. By contrast, human renal
cancer cells (RCC) do not secrete the cytokine and neither
express—both in vivo and in vitro—the IL-15Rγ chain (CD132) and
JAK3 [28]. In these cells, IL-15 drives the epithelial-mesenchymal
transition (EMT) [26,28]. In addition RCC express a tmb-IL-15
isoform, whose stimulation with the sIL-15Rα chain triggers a reverse
signal that induces E-cadherin down-regulation, triggering the EMT
process and thus promoting tumor progression [11].
In the present study, we reassess the biology of mb-IL-15 isoforms
by comparing primary cultures of human normal RPTEC, apparently
normal peritumoral cells (ptumTEC), and tumor-derived cells (RCC
and CSC/CD105+). Overall, our data indicate that mb-IL-15 and
tmb-IL-15 isoforms play a complex role in renal cancer homeostasis,
acting on cell phenotype, tumor microenvironment, and cell survival.Materials and Methods
Antibodies, Cytokines, and Reagents
Antibodies against IL-15 (L-20), TWIST (sc-15393), and β-actin
(sc-47778) were from Santa Cruz Biotechnology (Paso Robles, CA).
Antibodies against phospho Extracellular signal-Related Kinase
pERK1/2 (9101S), ERK1/2 (4695), pAKT (2967), and SNAIL
(3895S) were from Cell Signaling Technology (Danvers, MA).
Antibody against SLUG (MAB4371) was from Millipore (Billerica,
MA). The phycoerythrin (PE)–conjugated antibodies against IL-15
(IC2471P) and E-cadherin (FAB18381P), the recombinant humanIL-15Rα/Fc chimera soluble (sIL-15Rα) chain and Granulocyte
Macrophage-Colony Stimulating Factor (GM-CSF) were from
R&D Systems Europe Ltd (Abingdon, United Kingdom). The
PE-conjugated anti-APO2.7 monoclonal antibody (mAb) was from
Beckman Coulter (Roissy, France). 1,10-Phenanthroline (Phen) and
crystal violet were from Sigma-Aldrich (St Louis, MO). HRP-conjugated
secondary antibodies were from Jackson ImmunoResearch (West Grove,
PA), and the recombinant human non-glycosylated IL-15 (rhIL-15) was
from ImmunoTools (Friesoythe, Germany). The neutralizing anti–IL-15
M111 antibody was provided by Amgen (Thousand Oaks, CA). The
RAL 555 kit was from RAL Diagnostics (Martillac, France).
Primary Cells and Cell Lines
Primary normal RPTEC derived from a non-cancerous kidney were
purchased from Lonza Technologies (Verviers, Belgium) and expanded
in vitro following strictly manufacturer’s instructions. The REGM
medium culture of RPTECwas changed every day tomaintain epithelial
characteristics. In the absence of culture medium renewal, RPTEC lose
E-cadherin expression after 5 days, likely for the exhaustion of the
corticosteroids present in the REGMmedium that are powerful inducers
of E-cadherin [26]. Primary renal cultures were obtained by enzymatic
digestion of renal biopsies as described previously [29]. Primary tumoral
(RCC) and peritumoral (ptumTEC) cells were derived from the same
patient. Peritumoral cells were isolated from “apparently normal” renal
fragments surrounding the neoplastic lesion and display in vitro normal
morphology, contact inhibition of proliferation, and limited life span,
whereas primary RCC derived from tumor biopsies generate permanent
cell lines that at confluence continue to proliferate. PtumTEC also lack
both in vivo and in vitro the expression of CD132 that differentiates
RCC from normal tubular ones and exhibit IL-15R assembly, response
to soluble IL-15, and immunomodulatory properties, similar to those
detected in RCC [26,28].
RCC primary cultures, ptumTEC, established RCC cell lines
ACHN, HIEG, RCC5, and RCC7, and U937 (human leukemic
monocyte lymphoma cell line) were grown in RPMI 1640 supple-
mented with 10% fetal calf serum, 1% minimum essential medium
sodium pyruvate, and 1% penicillin/streptomycin (all products from
Life Technologies, Carsbad, CA). The erythroleukemia cell line TF-1β
was maintained in complete RPMI 1640 supplemented with 5 ng/ml
GM-CSF and 250μg/ml geneticinG418. Renal cancer stem cells CSC/
CD105+ were identified and isolated from human renal carcinoma as
previously described [30]. Monocytes were purified from peripheral
blood mononuclear cells by using the CD14-Adembeads (Ademtech,
Pessac, France).
Stimulations and Treatments
Acidic shock was performed by incubating cells in ice-cold 0.1 M
sodium acetate (pH 3.5) for 15 minutes at 4°C. Incubation in
phosphate-buffered saline was used as a control. Metalloprotease
sensitivity was evaluated by incubating epithelial cells with ortho-
pervanadate (PVN, 200 μM) or with phorbol ester phorbol
12-myristate 13-acetate (PMA, 200 ng/ml) in fetal calf serum–free
medium at 37°C for 1 and 3 hours, respectively. Competition
experiments were performed by incubating the cells with a broad-
spectrummetalloprotease inhibitor Phen (2mM) [21]. For biochemical
analysis, culture supernatants (SNT) were collected after treatments,
filtrated (0.22 μm), and concentrated 20-fold using Amicon Ultra-4,
Ultracel-10K (Millipore). Soluble IL-15 in the SNT was analyzed by
Western blot, and bioactivity assays were performed on TF-1β cells.
Neoplasia Vol. 17, No. 6, 2015 Interleukin-15 isoforms and functions in human renal cells Azzi et al. 511Flow Cytometry
For all assays described below, fluorescence data for 10,000 to
50,000 events were acquired on a FACSCalibur flow cytometer (BD
Biosciences, Oxford, United Kingdom), and data were analyzed using
version vX.0.7 of FLOWJO software (Treestar, Ashland, OR). Each
experiment was repeated at least three times.
Immunoblot Analysis
All Western blot analyses were performed as previously described
[11]. For N-glycanase treatment, phosphate-buffered saline–washed
RCC were lysed for 15 minutes at 4°C in 1% Triton X-100, 50 mM
sodium phosphate buffer (pH 7.8), 150 mM NaCl, and protease
inhibitor cocktail (complete tablets; Roche). After 30-minute
centrifugation (14,000 rpm, 4°C), the supernatants were incubated
in the presence or absence of 6 μl/100 μl (6 U) of N-glycanase
(Roche, Indianapolis, IN) at 37°C for 18 hours. Proteins were
separated on a 15% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and IL-15–immunoblotted as described above.
In Vitro Scratch Assay
In vitro scratch assay was performed as previously described [31].
Briefly, cells were pretreated or not (control condition) with sIL-15Rα
(100 ng/ml) for 5 days and seeded in a six-well plate (400,000 cells per
well) and allowed to reach confluence (24 hours). Cells were then
scratched and shifted to a serum-freemedium in the presence or absence
of sIL-15Rα (100 ng/ml). Analysis was performed 24 hours later. Cells
were fixed and stained using the RAL 555 kit, and images were acquired
using fluorescence microscopy (Leica, Wetzlar, Germany).
Transwell Invasion Assay
Invasion assay was performed in Boyden chambers (polycarbonate
filters of 8 mm pore size, precoated with Matrigel matrix). Cells
(3 × 105) in 300 ml of medium (containing 0.1% FBS) with or
without 100 ng/ml sIL-15Rα chain were seeded in the upper
chamber. Six hundred microliters of medium with 10% FBS were
added to the lower chamber and served as a chemotactic agent.
After 4-day incubation, Matrigel was mechanically removed from
the filter with a cotton swab. The cells adhering to the underside
of the filter were fixed and stained with crystal violet and analyzed
under an upright microscope (five fields per chamber).
Bioactivity Assays
GM-CSF–starved TF-1β cells were cultured at a concentration of
5 × 103 cells per well in microtiter plates in 50 μl of culture medium
containing increasing concentrations of rhIL-15 or supernatant of
PMA-treated RCC (10% final). To evaluate IL-15 activity, SNT were
preincubated for 30minutes with 10μg/ml neutralizing anti–IL-15mAb
M111. Early-stage apoptosis induction was determined by measuring
the expression of the mitochondrial membrane protein APO2.7 (7A6
antigen) using a PE-labeled antibody as well as the respective isotype
control by flow cytometry.
Serum Starvation and Cell Death Detection
CSC/CD105+ were seeded in T25 culture flasks in complete
medium. The day after, the medium was replaced with fresh
medium without fetal calf serum for starvation. Controls included
untreated cells or cells treated with DMSO (1/1000); sister cultures
were treated with sIL-15Rα (100 ng/ml) or with sIL-15Rα plus
1 μΜ ΜΚ-2206 (1 mM stock solution in DMSO) or with 1 μΜ
ΜΚ-2206 alone (not shown). All treatments were performed induplicate, and the experiment was repeated three times. After
48 hours of culture, cells were collected, and programmed (apoptosis)
and non-programmed (necrosis) cell death were determined using
Annexin V–FITC Apoptosis Detection Kit (e-Bioscience, San Diego,
CA) according to the manufacturer's protocol. Analysis was
performed by flow cytometry using Cell Quest software (FACScan;
Becton Dickinson, Franklin Lakes, NJ).
Results
Renal Normal and Tumor-Derived Cells Express Different
mb-IL-15 Isoforms
To characterize the type of IL-15 isoforms expressed in the
different components of renal clear cell carcinoma, we took advantage
of normal and tumoral epithelial cells, cancer stem cells from renal
origin, and also peritumoral renal cells (ptumTEC). Indeed, the road
to cancer begins long before the growth of a clinically detectable
lesion, with the replacement of the normal cells by histologically
non-dysplastic but pro-tumorigenic cells (field cancerization) that
subsequently coexist and share with the nearby cancer cells several
epigenetic alterations [32]. In this context, we integrated herein the
analysis of renal ptumTEC that for their properties likely represent
cells belonging to a field cancerization that up to now had not yet
been identified in renal clear cell carcinoma.
Analyzing by flow cytometry the expression of IL-15 in these different
cell subtypes, we show that normal, peritumoral, and tumor-derived
cells (RCC and CSC/CD105+) constitutively express an mb-IL-15
resistant to acidic shock, with the exception of normal RPTEC, where
IL-15 is shed from the cell surface by a pH 3.5 treatment (Figure 1A).
These data indicate that RPTEC likely express a mb-IL-15 anchored at
the cell membrane through the IL-15Rα chain [5,9], while ptumTEC,
RCC, andCSC express a transmembrane IL-15 (tmb-IL-15) [1,10–12].
Western blot analysis of the recombinant non-glycosylated cytokine,
used as control, shows the 12.5 kDa canonical monomeric band and a
dimeric band around 25 kDa (Figure 1B) likely formed by self-
aggregation of the cytokine [33]. Immunoblot analysis of cell lysates
with the anti–IL-15 L20 antibody shows that normal RPTEC express
two IL-15 isoforms with apparent molecular mass of 14 and 16 kDa,
which likely represent two different N-glycosylated patterns of the
cytokine [34]. These isoforms were also found in LipoPolySaccharide
(LPS)-treated human monocytes and in the Interferon (IFN)-γ–treated
macrophage cell line U937. The abovementioned IL-15 isoforms are
faintly expressed in peritumoral (RCC5-ptumTEC and Pil-ptumTEC),
tumoral (HIEG, RCC7, ACHN, RCC/CD105−), and CSC/CD105+
that in addition contain, as main form, a band close to 27 kDa,
previously observed only in RCC [11].
Mb-IL-15 Is N-glycosylated in RCC
In eukaryotic cells, N-linked glycosylation is necessary for IL-15
complete processing and secretion [34]. Although IL-15 displays
N-glycosylation on two of three potential glycosylation sites
(Asn-X-Ser/Thr) in the mature protein, there are no available data
on the role of N-linked glycosylation in the expression of the
tmb-IL-15 isoforms. Overnight exposure of RCC to tunicamycin
(1 and 10 μg/ml), an inhibitor of N-linked glycosylation, causes
dose-dependent inhibition of the tmb-IL-15 expression on these cells
(Figure 2A). Tunicamycin withdrawal (Figure 2B) allows, within
48 hours, the recovery of tmb-IL-15 expression, which is dependent
not only on N-linked glycosylation but also on protein neosynthesis
because cycloheximide inhibited this effect. These data show that
Figure 1.Mb-IL-15 characterization in human renal normal and tumor-derived cells. (A) FACS analysis of membrane IL-15 expression on
epithelial cells after acidic shock. Primary normal (RPTEC), peritumoral (ptumTEC), tumoral (RCC) epithelial cells and cancer stem cells
(CSC/CD105+) were treated or not with acidic buffer (pH 3.5) before staining with anti–IL-15 monoclonal antibody. These data are
representative of three independent experiments. (B) Western blot analysis performed with anti–IL-15 L20 antibody detects different IL-15
isoforms in the total lysates from primary normal (RPTEC), peritumoral (RCC5-ptumTEC and Pil-ptumTEC), tumoral RCC cell lines (RCC7,
HIEG, ACHN, and RCC/CD105−) and CSC/CD105+.
Figure 2. Characterization of mb-IL-15 isoforms in RCC. (A) FACS analysis of membrane IL-15 expression on RCC. Cells were treated
overnight with 1 or 10 μg/ml tunicamycin (Tuni, an inhibitor of N-linked glycosylation) or (B) with 20 μg/ml cycloheximide (CHX, a protein
synthesis inhibitor). In some experiments, overnight-treated tunicamycin cells were washed three times and cultured for an additional
48 hours in freshmedium in the absence or presence of CHX for the last 24 hours. Mb-IL-15 expression in untreated (black) or treated cells
(gray) was analyzed using an anti–IL-15 monoclonal antibody. White histograms refer to isotype-matched control. A representative
experiment out of three is shown. (C) Immunoblots on total RCC cell lysates of N-glycanase digested and mock digested samples. Varied
amounts of extracts were applied to a 15% sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Release of oligosaccharides after
N-glycanase treatment (right panel) was monitored by immunodetection of altered protein band migration.
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that requires optimal N-linked glycosylation and protein synthesis.
Western blot analysis in the RCC cell lysate (Figure 2C) shows that
N-glycanase treatment leads to the loss of the isoforms ranging
between 16 and 27 kDa and the acquisition of an under-glycosylated
isoform around 13 to 15 kDa. These data strongly suggest that
27 kDa represents a hyper-glycosylated isoform of the cytokine that
could be due either to the engagement of the third potential
glycosylation site [34] or to an excess of N-glycosylation of the two
described sites.Figure 3.Metalloprotease sensitivity and biologic activity of the releas
of mb-IL-15 in RPTEC, ptumTEC, RCC, and CSC/CD105+, after 1-hou
metalloprotease inhibitor Phen (2 mM). These data are representative
anti–IL-15 L20 antibody in total cell lysates (TL, 25 μg) and 50-fold conc
with 200 ng/ml PMA for 3 hours. rhIL-15 (5 ng) was used as specific
through IL-15Rαβγ receptors. TF-1β cells were GM-CSF depriv
concentrations of rhIL-15, or supernatant of 3-hour PMA-treated
neutralizing anti–IL-15 monoclonal antibody M111. To determine th
mitochondrial membrane protein APO2.7 was measured using a PE
IgG1-PE) by flow cytometry. The percentage of APO2.7 positive cells
identical experiments.Released mb-IL-15 from Renal Epithelial Cells Is Metalloprotease-
Dependent and Biologically Active
To investigate whether mb-IL-15 isoforms are metalloprotease
sensitive, primary RPTEC, peritumoral (ptumTEC), tumoral (RCC)
epithelial cells, and CSC/CD105+ cells were incubated for 1 hour in
the presence of PVN or PMA for 3 hours. Both treatments cause the
loss of mb-IL-15 expression in all tested cultures, while exposure to
Phen (a wide spectrum metalloprotease inhibitor) counteracts the
effects of PVN and PMA indicating that the cleavage of the mb-IL-15
is mediated by metalloproteases (Figure 3A). To analyze the releaseded mb-IL-15 from renal epithelial cells. (A) Flow cytometry analysis
r treatment with ortho-PVN (200 μM) in the presence or absence of
of three independent experiments. (B) Western blot analysis with
entrated supernatant (SNT, 25 μl) of RPTEC and RCC treated or not
control. (C) Released mb-IL-15 protects TF-1β cells from apoptosis
ed and cultured with rhGM-CSF (positive control), increasing
RCC (SNT-PMA-RCC) in the absence or presence of 10 μg/ml
e induction of apoptosis in an early stage, the expression of the
-labeled antibody as well as the respective isotype control (mouse
is indicated for each cell treatment. Data are representative of three
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concentrated supernatants from RPTEC and RCC before and after
exposure to PMA (Figure 3B). The 16-kDa IL-15 isoform, observed
in the RPTEC cell lysate, was barely detectable in the supernatant
from untreated cells (SNT-BA) and significantly increased in the
supernatant collected after PMA treatment (SNT-PMA). By contrast,
in supernatants of RCC, we only detected a 25-kDa band that was
strongly enhanced after exposure to PMA. To determine if the
hyper-glycosylated IL-15 isoforms released by PMA-treated RCC
exerts a biologic activity, the erythroleukemic cell line TF-1β, whose
survival and proliferation are GM-CSF– or IL-15–dependent, was
used [35]. The anti-apoptotic activity of IL-15 present in
SNT-PMA-RCC on TF-1β was evaluated by analyzing the surface
expression of the apoptotic marker APO2.7 (Figure 3C), whose
expression is strongly induced after 72-hour GM-CSF starvation
(50%). While monomeric rhIL-15 protects TF-1β cells from
apoptosis in a dose-dependent manner (10 pg/ml, 34% to 10 ng/ml,
6% of apoptotic cells), treatment of TF-1β cells with SNT-PMA-RCC,
containing cleaved tmb-IL-15, causes a powerful anti-apoptotic effect
similar to that obtained using 1 ng/ml rhIL-15. Use of the neutralizing
anti–IL-15 mAb M111 markedly inhibits, after 72 hours, the
anti-apoptotic effect of rhIL-15 (1 ng/ml, 39%), as well as the
SNT-PMA-RCC (61%), while added alone it had no effect (data not
shown), demonstrating therefore that the anti-apoptotic effect is
promoted by the released IL-15.
Tmb-IL-15Mediates Reverse Signaling inRenal Tumor–Derived
Cells but Not in Normal Cells
Tmb-IL-15 displays a potential to induce bidirectional signaling,
whereas mb-IL-15 transpresented by the IL-15Rα chain only activates
bystander cells. For this reason, we investigated the competence of the
mb-IL-15 expressed by the different human renal cells to mediate the
outside-to-inside signal transduction in response to soluble specific
ligands [11]. Stimulation with 100 ng/ml sIL-15Rα triggers the
phosphorylation of the Mitogen-Activated Protein (MAP) kinase
ERK1/2 in all examined tumor-derived cells but not in RPTEC
(Figure 4A). These data clearly state that ptumTEC, RCC, and CSC,
but not the RPTEC, express an mb-IL-15 able to mediate a reverse
signaling after activation by a soluble ligand. Because RCC treated with
sIL-15Rα underwent epithelial-mesenchymal transdifferentiation [11],
we tested the effects of reverse signaling on the abovementioned cells,
analyzing the expression of the epithelial marker E-cadherin. Five days
of treatment with the sIL-15Rα chain (100 ng/ml) causes the loss of this
epithelial marker on ptumTEC and RCC, whereas it had no effect on
RPTEC and CSC (Figure 4B), suggesting that in the latter ones
tmb-IL-15–dependent reverse signal is not competent to modify
E-cadherin expression. This event was associated with an enhanced
expression of the transcription factors, SNAIL and SLUG in RCC,
confirming that these factors are involved in the sIL-15Rα–induced
EMT process. As expected, both transcription factors were not detected
in RPTEC (Figure 4C). We further checked what could be the
functional effect of the sIL-15Rα–induced reverse signaling. Using an
in vitro scratch assay, we show that sIL-15Rα treatment allowed a
nearly complete wound healing in 24 hours only in RCC. We also
addressed the invasive properties of tumor cells treated or not with
sIL-15Rα chain and show that treated cells highly invaded the Matrigel
matrix in comparison to untreated ones. Taken together, these data
indicate that the sIL-15Rα–mediated reverse signaling favors a
migratory/invasive phenotype in tumor cells.Tmb-IL-15 Mediates Reverse Signaling in CSC/CD105+
Inducing Protection from Cell Death
It has been reported that tmb-IL-15–dependent reverse signal
controls cancer cell secretion of pro-inflammatory cytokines, cell
migration [1,12], or EMT induction [11]. Because in CSC/CD105+
tmb-IL-15–dependent reverse signal does not modify E-cadherin
expression, we explored other biologic parameters usually controlled
by IL-15 such as cell survival. Therefore, we tried to induce cell death
subjecting CSC to prolonged serum starvation and to study whether a
single stimulation of the tmb-IL-15 with 100 ng/ml sIL-15Rα chain
could assure CSC survival in these conditions. Flow cytometry
analysis shows that serum starvation essentially induces cellular
necrosis [propidium iodide+ (PI+)/Annexin V− cells] and very limited
apoptosis (PI+/Annexin V+ cells) and that sIL-15Rα chain rescues
about 70% of CSC from non-programmed cell death (Figure 5, A
and B). We next investigated what signaling pathway might be
associated with CSC cell survival. Protection from non-programmed cell
death may be induced through the activation of the AKT pathway [36].
In Figure 5C,Western blot analysis shows that inCSC/CD105+, reverse
signal triggered by the sIL-15Rα chain activates the AKT pathway, while
the use of the AKT-specific inhibitor MK-2206 [37] counteracts the
protective effect induced by the sIL-15Rα chain (Figure 5D).
Discussion
Experiments in IL-15(−/−) and IL-15Rα(−/−) mice show that the
production of intrarenal IL-15 is involved in renal cell survival and
homeostasis, and it has been hypothesized that the dominant
intrarenal IL-15 isoform is probably represented by the mb-IL-15
anchored at the cell surface through the IL-15Rα [24,25].
Subsequently, several papers have reported the in vitro production
of IL-15 by both murine and human normal renal epithelial cells, but
in no instance the expression of mb-IL-15 has been demonstrated
[20,24,25,21]. A major distinguishing feature between normal
RPTEC and peritumoral (ptumTEC) and renal cancer–derived
ones (RCC and CSC) is represented by the expression of different
mb-IL15 isoforms. Indeed, RPTEC express, similarly to monocytic
cells of normal or neoplastic origin, a cell surface 16-kDa IL-15
sensitive to acidic buffer treatment (pH 3.5) and not competent for
inducing a reverse signaling in response to sIL-15Rα. This isoform
therefore represents the classic mb-IL-15 anchored through the
IL-15Rα chain, competent for transactivation of bystander cells
through juxtacrine loops [1,8,9,14,38].
In contrast, ptumTEC and CSC/CD105+, like RCC [11],
constitutively express a functional 27-kDa transmembrane IL-15
isoform (tmb-IL-15), since it is resistant to acidic buffer treatment
and delivers a reverse signal following stimulation with its soluble
ligand [1,10–12]. We had previously hypothesized that the 27-kDa
tmb-IL-15 could represent an IL-15 homodimer [11]. However,
further biochemical characterization shows that the 27-kDa
tmb-IL-15 is a hyper-N-glycosylated isoform. Indeed, a homodimeric
27-kDa IL-15 should, after deglycosylation, display a molecular
weight of 25 kDa similar to that exhibited by the self-aggregated and
unglycosylated recombinant IL-15. By contrast, treatment of RCC
cell lysates with N-glycanase causes the loss of different IL-15
N-glycosylated isoforms (16 to 27 kDa) and the generation of
under-glycosylated isoforms 13 to 15 kDa, rendering unlike the
homodimeric hypothesis. In addition, IL-15 homodimers generated
by self-aggregation of recombinant unglycosylated IL-15 do not
exhibit biologic activity owing to the self-aggregation process [33],
Figure 4. Mb-IL-15 mediates reverse signaling in RCC, ptumTEC, and CSC/CD105+ but not in RPTEC. (A) Time course Western blot
analysis of MAP kinase ERK1/2 activation in RPTEC, ptumTEC, RCC, and CSC/CD105+ stimulated with 100 ng/ml sIL-15Rα chain.
Membranes were reblotted with an anti-ERK1/2 antibody used as loading control. A representative experiment out of three is shown. (B)
FACS analysis of E-cadherin surface expression in RPTEC, ptumTEC, RCC, and CSC/CD105+, after 5 days of stimulation with sIL-15Rα
chain (100 ng/ml). RPTEC were cultured in fresh medium every day to maintain epithelial morphology. In these cells, treatment with
sIL-15Rα chain was also renewed every day. Gray and black histograms represent E-cadherin expression in treated or untreated cells,
respectively. White histograms refer to isotype-matched control. The data are representative of four separate experiments. (C) Time
course Western blot analysis of SNAIL and SLUG activation in RPTEC and RCC stimulated with 100 ng/ml sIL-15Rα chain. β-Actin was
used as loading control. Images were quantified using ImageJ software. (D) In vitro scratch assay in RPTEC and RCC after stimulation with
sIL-15Rα chain (100 ng/ml). Cells were treated with sIL-15Rα for 5 days and scratched, and images were acquired 24 hours later.
(E) Transwell invasion assay in RCC. After 4 days of sIL-15Rα chain (100 ng/ml) treatment, cells adhering to the underside of the filter were
fixed and stained with crystal violet and analyzed under an upright microscope (five fields per chamber).
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following PMA treatment (25 kDa) displays a powerful biologic
activity, because it protects hematopoietic cells from apoptosis, thus
excluding the homodimer hypothesis. Moreover, the treatment withtunicamycin and cycloheximide shows that on RCC tmb-IL-15
appears to undergo a rapid turnover that strictly depends on an
optimal N-glycosylation and protein neosynthesis. These latter
parameters further distinguish the RCC tmb-IL-15 isoform from
Figure 5. Reverse signaling through transmembrane IL-15 in CSC/CD105+. (A) Dot plot analysis and (B) statistical analysis of cell death
triggered by serum starvation and protective effect induced by sIL-15Rα. Black circles identify cells undergoing non-programmed cell
death (PI+/Annexin V− cells). (C) Western blot analysis of AKT activation induced by sIL-15Rα. (D) Statistical analysis of non-programmed
cell death triggered by serum starvation, protective effect induced by sIL-15Rα, and inhibition of survival effect by the MK-2206 AKT
inhibitor. Starvation-induced cell death was set at 100%. Each figure is representative of at least three independent experiments. *P b .05,
**P b .01, and ***P b .005 compared to control by paired Student’s t test.
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of the complex is expressed and persists at the cell membrane up to
72 hours [9].
Interestingly, activation of a reverse signal through stimulation of
the tmb-IL-15 with sIL-15Rα causes the down-regulation of
E-cadherin in RCC and ptumTEC but not in CSC. In the latter
ones, serum starvation induces the non-programmed death, which is
inhibited by the tmb-IL-15–induced reverse signal through the
activation of the survival AKT pathway [36]. The protection from
cellular necrosis, through the tmb-IL-15–induced reverse signal, is a
novel observation that sheds a new light on the multiple biologic
properties of tmb-IL-15 and could represent an additional mecha-
nism functionally defining the CSC niche [39].
The present data and previous ones [26,28] indicate that
peritumoral epithelial renal cells express an IL-15 system similar to
the one observed in RCC [11,26,28]. Thus, activation of the IL-15
system in ptumTEC, through the loss of E-cadherin, could contribute
to organize around the tumor a crown of “pre-neoplastic” cells that,
losing their polarization, would become more prone to neoplastic
transformation favoring tumor progression [40]. In this context, the
depletion of E-cadherin is per se sufficient to promote the migratory and
invasive potential of embryonic kidney epithelial cells [41,42] In
addition, the loss of E-cadherin was observed in premalignant foci of
Von Hippel-Lindau patients, which concomitantly showed increasedCAIX expression, suggesting that E-cadherin loss is an early tumorigenic
event [43]. Finally the loss of E-cadherin could drastically modify the
repertoire of tumor infiltrating regulatory T lymphocytes whose
intratumor homing is strictly dependent on the E-cadherin/CD103
interaction [44,45].
In conclusion, these data show that IL-15 acts not only as sensor of
the normal epithelial homeostasis but also plays a major role in the
pathophysiology of human renal epithelial cells modifying both
epithelial cells and their microenvironment.
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